March 3,
2026
Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Our Mission, Our Passion
To help people not only live longer, but live better
Recognized Explorers,
Remarkable Experience
We have assembled a team with significant small molecule drug discovery, development and commercialization expertise.
Novel Insights,
Precision Therapeutics
We believe the success of next generation therapeutics depends not only on clinical efficacy, but also on a differentiated product profile, including tolerability, dosing regimen, and specific drug administration requirements, that drives widespread adoption by physicians and patients in the real world.
Latest News
Recently Published
Preliminary safety and efficacy of ELVN-001, a selective active site inhibitor of BCR::ABL1, in patients with CML driven by atypical fusion transcripts
67th Annual American Society of Hematology Annual Meeting | December 2025